上海美迪西生物医药股份有限公司 2023 年年度股东大会会议资料 证券代码：688202 证券简称：美迪西 上海美迪西生物医药股份有限公司 2023 年年度股东大会会议资料 二〇二四年五月 上海美迪西生物医药股份有限公司 2023 年年度股东大会会议资料目录 | 2023 年年度股东大会会议须知 | 1 | | --- | --- | | 2023 年年度股东大会会议议程 | 4 | | 议案一：关于公司《2023 年度董事会工作报告》的议案 | 6 | | 议案二：关于公司《2023 年度监事会工作报告》的议案 | 11 | | 议案三：关于公司《2023 年度独立董事述职报告》的议案 | 15 | | 议案四：关于公司《2023 年度财务决算报告》的议案 | 16 | | 议案五：关于公司 2023 年度利润分配预案的议案 | 22 | | 议案六：关于公司《2023 年年度报告》及摘要的议案 | 24 | | 议案七：关于续聘公司 2024 年度审计机构及内控审计机构的议案 | 25 | | 议案八：关于公司董事薪酬方案的议案 | 26 | | 议案九：关于公司监事薪酬方案的议案 | 27 | | 议案 ...

证券代码：688202 证券简称：美迪西 公告编号：2024-027 上海美迪西生物医药股份有限公司 关于回购股份事项前十名股东和前十名无限售条件 股东持股情况的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 上海美迪西生物医药股份有限公司（以下简称"公司"）于 2024 年 4 月 26 日召开第三届董事会第二十一次会议，审议通过了《关于以集中竞价方式回购公 司股份方案的议案》，具体内容详见公司于 2024 年 4 月 29 日在上海证券交易所 网站(www.sse.com.cn)披露的《上海美迪西生物医药股份有限公司关于以集中竞 价交易方式回购股份方案的公告》（公告编号：2024-024）。 根据《上市公司股份回购规则》《上海证券交易所上市公司自律监管指引第 7 号——回购股份》等相关规定，现将公司第三届董事会第二十一次会议决议公 告的前一个交易日（即 2024 年 4 月 26 日）登记在册的前十名股东和前十名无限 售条件股东的名称、持股数量和持股比例情况公告如下： | 序号 | 股东名称 | 持股数量（股） ...

集中竞价交易方式回购公司股份方案的公告》（公告编号：2023-065）、《上海美迪 西生物医药股份有限公司关于以集中竞价交易方式回购公司股份的回购报告书》 （公告编号：2023-068）。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2023/11/14，由公司实际控制人、董事长陈金章先 | | | --- | --- | --- | | | 生，实际控制人、董事、总经理 先生提议 | CHUN-LIN CHEN | | 回购方案实施期限 | 年 月 年 月 日 2023 11 13 日~2024 12 | | | 预计回购金额 | 2,000.00 万元~4,000.00 万元 | | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 | | | | □为维护公司价值及股东权益 | | | 累计已回购股数 | 万股 69.1738 | | | 累计已回购股数占总股本比例 | 0.5136% | | | 累计已回购金额 | 万元 3,787.53 | | | | ...

关于以集中竞价交易方式回购股份的回购报告书 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ● 回购股份金额：回购资金总额不低于人民币 1,000 万元（含），不超过人民 币 2,000 万元（含）； 证券代码：688202 证券简称：美迪西 公告编号：2024-028 上海美迪西生物医药股份有限公司 ● 回购股份资金来源：上海美迪西生物医药股份有限公司（以下简称"公司"） 自有资金； ● 回购股份用途：本次回购股份将在未来适宜时机全部用于股权激励或员工 持股计划，并在股份回购实施结果暨股份变动公告后三年内予以转让；若公司未 能将本次回购的股份在股份回购实施结果暨股份变动公告日后三年内转让完毕， 未转让股份将被注销。如国家对相关政策做调整，则本回购方案按调整后政策实 行； ● 回购股份价格：不超过人民币 60 元/股（含），该价格不超过董事会通过回 购股份决议前 30 个交易日公司股票交易均价的 150%； ● 回购股份方式：集中竞价交易； ● 回购股份期限：自公司董事会审议通过本次回购股份方案之日起6 个 ...

Group 1: Company Expansion and Strategy - The company plans to establish a multi-point layout in key overseas industrial areas, enhancing the business team's construction and increasing the frequency of centralized expansion and training to adapt to overseas market competition [3] - The company has invested in a research laboratory in Boston, USA, covering areas such as chemistry, biology, and animal experiments, which will serve as a strategic point for global deployment [3][4] - The company aims to gradually increase the proportion of overseas business to provide new ideas, directions, and momentum for development and growth [3] Group 2: Investment Projects and Capacity Planning - The company has over 85,000 square meters of R&D office space in various locations, including Zhangjiang Hi-Tech Park and Boston [4] - The main structure of the "Drug Discovery and Pharmaceutical Research and Application Platform Laboratory Expansion Project" has been completed and is awaiting acceptance, which will enhance the scale and level of new drug R&D services [4] - The "Medici North Shanghai Biopharmaceutical R&D Innovation Industrial Base Project" has officially commenced construction, with steady progress planned based on business development [4] Group 3: R&D Technology and Trends - The company focuses on market demand, tracking global hot drug research directions, and enhancing the integrated R&D platform for ADC drugs and oligonucleotide drugs [5] - As of the end of 2023, the company has assisted clients in completing dozens of ADC preclinical studies, with 24 projects approved by NMPA and FDA entering clinical trial stages [5] - The company is committed to advancing key technology research in hot drug development, including platforms for oligonucleotide drug R&D and AI-based innovative drug preclinical services [5] Group 4: Human Resource Management - The company emphasizes the establishment of a technical talent team and management talent team to meet business needs, focusing on internal talent development [6] - In 2023, the company streamlined organizational structures and integrated professional resources across departments to enhance personnel efficiency [6] Group 5: Industry Outlook - Despite the current challenges in the biopharmaceutical investment environment, there are new opportunities arising from the continued activity in drug categories like GLP-1, ADC, and oligonucleotides [7] - The Chinese government is actively exploring policies to support the development of innovative drug industries, including increased funding for life sciences research and reforms in drug pricing mechanisms [7][8] - Recent government reports emphasize the importance of technological innovation in leading industry innovation, which is expected to provide more opportunities for domestic CRO companies [7][8]

广发证券股份有限公司 关于上海美迪西生物医药股份有限公司 2023 年度持续督导跟踪报告 根据《证券发行上市保荐业务管理办法》《上海证券交易所科创板股票上市 规则》等有关法律、法规的规定，广发证券股份有限公司（以下简称"广发证券"、 "保荐机构"）作为上海美迪西生物医药股份有限公司（以下简称"美迪西"、 "公司"）向特定对象发行 A 股股票并上市的保荐机构，负责美迪西的持续督导 工作，并出具本年度持续督导跟踪报告。 2023 年度，广发证券对美迪西的持续督导工作情况总结如下： | 一、持续督导工作情况 | | --- | | 序号 | 工作内容 | 实施情况 | | --- | --- | --- | | | 建立健全并有效执行持续督导工作制度，并 | 保荐机构已建立健全并有效执行 | | 1 | 针对具体的持续督导工作制定相应的工作计 | 了持续督导制度，已制定了相应的 | | | 划。 | 工作计划。 | | 2 | 根据中国证监会相关规定，在持续督导工作 | 保荐机构已与美迪西签订保荐协 | | | 开始前，与上市公司或相关当事人签署持续 | 议，该协议已明确了双方在持续督 | | | 督导协议，明确双 ...

Financial Performance - In Q1 2024, the company's operating revenue decreased by 42.51% compared to the previous period, primarily due to intensified competition in the pharmaceutical industry, leading to lower order prices and delays in order execution [14]. - The net profit attributable to shareholders of the listed company fell by 136.98% in Q1 2024, significantly impacted by the decline in revenue [14]. - The net profit attributable to shareholders after deducting non-recurring gains and losses decreased by 140.77% in Q1 2024, also primarily due to the drop in revenue [14]. - The company reported a comprehensive loss of ¥37,430,250.14 for the current period, contrasting with a comprehensive income of ¥101,414,263.08 in the same period last year [29]. - Basic and diluted earnings per share were both reported at -¥0.28, down from ¥0.84 in the previous year [29]. - The company's operating revenue for the reporting period was approximately ¥259.51 million, representing a decrease of 42.51% compared to the same period last year [36]. - The net profit attributable to shareholders of the listed company was approximately -¥37.56 million, a decline of 136.98% year-over-year [36]. - Net profit for Q1 2024 was a loss of CNY 37,555,731.42, compared to a profit of CNY 101,568,576.29 in Q1 2023, indicating a significant decline [55]. Cash Flow and Liquidity - The cash and cash equivalents as of March 31, 2024, were 311,034,580.34 RMB, down from 471,870,185.67 RMB at the end of 2023 [22]. - Cash flow from operating activities showed a net outflow of ¥58,554,399.06 compared to a net outflow of ¥17,443,008.18 in the previous year, indicating a worsening cash flow situation [30]. - The company's cash flow from operating activities was significantly impacted, with total cash outflows reaching ¥293,693,017.79 compared to ¥313,794,044.52 in the previous year [30]. - The net cash flow from operating activities was -¥58.55 million, indicating a significant decrease [37]. - The net increase in cash and cash equivalents was -¥160.84 million, compared to -¥53.51 million in the same period last year [37]. - The ending balance of cash and cash equivalents was approximately ¥310.53 million, down from ¥471.37 million at the beginning of the period [37]. - The company experienced a net cash outflow from financing activities of approximately -¥45.29 million, contrasting with a net inflow of ¥53.44 million in the previous year [37]. Assets and Liabilities - Total current assets decreased to ¥1,701,960,383.17 from ¥1,876,189,651.05, a decline of approximately 9.3% year-over-year [24]. - Total assets at the end of the reporting period were approximately ¥3.11 billion, a decrease of 4.62% from the previous year [37]. - Total liabilities decreased to CNY 656,483,576.12 from CNY 755,068,116.91, representing a decline of about 13.1% [48]. - Non-current assets totaled CNY 1,412,955,721.47, slightly up from CNY 1,389,657,829.49, an increase of 1.7% [48]. - The total non-current assets were reported at ¥1,000,000,000.00, with fixed assets valued at ¥660,680,905.37, down from ¥673,328,661.73 [24]. Research and Development - Research and development expenses totaled approximately ¥24.85 million, down by 12.42% year-over-year, while R&D expenses accounted for 9.57% of operating revenue, an increase of 3.29 percentage points [37]. - Research and development expenses for Q1 2024 were CNY 24,845,984.25, down from CNY 28,370,481.60 in Q1 2023, a decrease of 12.0% [55]. Government Support and Other Income - Government subsidies recognized in the current period amounted to 2,707,884.36 RMB, which are closely related to the company's normal business operations [6]. - The company reported a non-recurring gain of 2,678,490.04 RMB in Q1 2024, after accounting for tax effects [7]. - The fair value changes of financial assets and liabilities held by the company resulted in a gain of 472,183.08 RMB in Q1 2024 [6]. - The company did not identify any significant non-recurring gains or losses not listed in the relevant disclosure guidelines [14]. Market Strategy and Future Outlook - The company is focused on addressing the challenges posed by market competition and is exploring strategies for future growth and recovery [14]. - The company has not provided specific guidance for future performance or new product developments in the current report [50].

单位：元 证券代码：688202 证券简称：美迪西 公告编号：2024-025 上海美迪西生物医药股份有限公司 关于 2024 年第一季度计提资产减值准备的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、计提资产减值准备情况概述 2024 年第一季度确认的资产减值损失和信用减值损失总额为 3,800,321.94 元，具体情况如下表所示： | 序号 | 项目 | 本期计提准备金额 | 备注 | | --- | --- | --- | --- | | 1 | 信用减值损失 | 3,792,472.14 | 含应收账款坏账准备、其他 | | | | | 应收款坏账准备 | | 2 | 资产减值损失 | 7,849.80 | 含合同资产减值准备 | | | 合计 | 3,800,321.94 | | 二、本次计提资产减值准备的具体说明 （一）信用减值损失 公司以预期信用损失为基础，对应收账款、其他应收款等进行了分析和评估 并相应计提减值准备。2024 年第一季度公司合并报表口径发生信用减值损失合 计 3,792,472 ...

上海美迪西生物医药股份有限公司 第三届董事会第二十一次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、董事会会议召开情况 上海美迪西生物医药股份有限公司（以下简称"公司"）第三届董事会第二 十一次会议通知于 2024 年 4 月 19 日以电子邮件方式通知全体董事，本次会议于 2024 年 4 月 26 日以现场结合通讯方式召开。本次会议应到董事 8 人，实到董事 8 人。会议由公司董事长陈金章先生召集，经半数以上董事推举会议由董事、总 经理 CHUN-LIN CHEN 主持，监事和高级管理人员列席了会议。会议的通知、召开 及审议程序符合《中华人民共和国公司法》（以下简称"《公司法》"）等法律法规 以及《公司章程》的有关规定，会议合法有效。 二、董事会会议审议情况 会议经与会董事审议并书面表决通过了如下议案： 证券代码：688202 证券简称：美迪西 公告编号：2024-023 特此公告。 上海美迪西生物医药股份有限公司董事会 2024 年 4 月 29 日 （一）审议通过《关于公司<2024 年第一季度 ...

重要内容提示： 上海美迪西生物医药股份有限公司 关于以集中竞价交易方式回购股份方案的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 证券代码：688202 证券简称：美迪西 公告编号：2024-024 截至本公告披露日，公司暂未收到董事林长青、董事陈国兴、股东王国林、 股东上海美斓企业管理合伙企业（有限合伙）、股东上海美熹企业管理合伙企业（有 限合伙）、股东上海美劭企业管理合伙企业（有限合伙）、股东上海美甫投资管理 合伙企业（有限合伙）关于其未来 3 个月、未来 6 个月内是否存在减持公司股份 计划的书面回函。除上述人员外，公司董监高、实际控制人、回购提议人、持股 5%以上的股东在未来 3 个月、未来 6 个月暂无减持公司股份的计划，如后续有相 关减持股份计划，将严格按照中国证监会、上海证券交易所有关法律、法规及规 ● 回购股份方式：集中竞价交易； ● 回购股份期限：自公司董事会审议通过本次回购股份方案之日起6 个月内； ● 相关股东是否存在减持计划： 范性文件的相关规定及时告知公司并履行相关信息披露义务。 ● 相关 ...